Warsaw, [date] - Medicalgorithmics S.A., a provider of advanced AI-powered cardiac diagnostic solutions, has entered into a strategic alliance agreement with Singapore-based Care Vision Health Care Pte Ltd to commercialize its cardiac monitoring technologies in Malaysia and Singapore. Under the agreement, Care Vision will distribute Medicalgorithmics' Kardiobeat.ai ECG monitoring devices and offer ECG analysis services powered by the company's proprietary Deep Rhythm Platform and Deep Rhythm AI technology.
The agreement establishes a commercial framework for the distribution of ECG monitoring devices, with an initial target of 150 Kardiobeat.ai devices in Malaysia during the first 12 months following local regulatory registration. In addition to hardware sales, Medicalgorithmics expects to generate recurring revenues from ECG analysis services, with revenue growth linked to the number and duration of patient monitoring sessions.
The collaboration also includes the Wellysis S-Patch EX and EXL wearable ECG devices, broadening the portfolio of monitoring solutions available to healthcare providers in the region.
Southeast Asia represents an attractive growth opportunity for advanced cardiac diagnostics, supported by the increasing burden of cardiovascular diseases, expanding access to healthcare services, and growing interest in remote patient monitoring and AI-assisted medical technologies. Malaysia and Singapore offer opportunities for the adoption of ambulatory ECG monitoring solutions, particularly as healthcare providers seek more efficient and scalable diagnostic services. Through its partnership with Care Vision, Medicalgorithmics aims to establish a stronger commercial foothold in these markets and create a foundation for potential further expansion in the region.
The strategic significance of the agreement extends beyond the initial device distribution. By combining ECG monitoring hardware with AI-powered analysis services, Medicalgorithmics is establishing a scalable commercial model designed to generate recurring revenues as patient monitoring volumes increase.
The partnership represents another step in Medicalgorithmics' international expansion strategy, strengthening its commercial presence in Southeast Asia and supporting the broader adoption of its proprietary AI technologies through regional distribution partners.
The agreement has been concluded for an indefinite period, with implementation subject to applicable regulatory approvals and market adoption.
PROPOSED CEO QUOTE - SUBJECT TO APPROVAL
"Southeast Asia is an important market for our international growth strategy. We see significant opportunities for AI-powered cardiac diagnostics as healthcare providers increasingly adopt remote monitoring and digital technologies. Our partnership with Care Vision combines local market expertise with our proprietary ECG analysis technology, creating a scalable foundation for long-term growth and recurring revenues in the region."
- Kris Siemionow, CEO of Medicalgorithmics S.A.
- October 27, 2026
